Recursion Pharmaceuticals, Inc. — Cyborg Score 7/10
Strong
Biotechnology / AI-Driven Drug Discovery (TechBio)
Strategic Profile
Recursion differentiates itself through its integration of wet labs, bioinformatics, and NVIDIA-backed supercomputing (BioHive-2) to generate millions of multi-omic data points weekly and train machine learning models at scale. The company has established strategic partnerships with major pharma (Roche, Genentech, Takeda, Bayer) and is advancing a pipeline across oncology, rare disease, and neuroscience with multiple programs in clinical trials.
Cyborg Score Rationale
Recursion demonstrates strong technology differentiation and institutional backing, with recent ARK Investment purchases and positive clinical momentum (TUPELO trial results). However, the company faces significant financial headwinds with persistent net losses and cash burn, requiring careful monitoring of runway and execution timelines.
Top Insights
Recent NVIDIA GTC conference showcase highlights collaboration on AI-driven automated drug discovery labs, signaling validation of technology approach and attracting institutional attention
Leadership transition in January 2026 with Najat Khan becoming CEO signals strategic refresh and continuation of innovation-focused strategy
Strong liquidity position ($667M cash at Q3 2025) enables runway for clinical development, though company continues to operate at a loss with elevated R&D spend exceeding $121M
Partnership ecosystem expanding with Roche milestone of $30M for microglial immune cell mapping, demonstrating revenue-generating collaborations alongside internal pipeline development
Named Competitors
Exscientia — AI-designed drug discovery with focus on small molecules
Tempus AI — Generative AI applied to clinical data and drug discovery
Atomwise — Physics-based AI platform for molecular design
Moderna/Vertex — Established biotech with strong R&D capabilities and market presence
Recent Developments
(February 2026) Featured at NVIDIA GTC conference for AI-driven high-throughput drug discovery collaboration with HighRes Biosolutions